Jean-Paul Prieels
Direttore/Membro del Consiglio presso DNAlytics SA
Provenienza dei contatti di primo grado di Jean-Paul Prieels
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Université Catholique de Louvain
59
| College/University | Other Consumer Services | 59 |
Université Libre de Bruxelles
19
| College/University | Other Consumer Services | 19 |
Themis Bioscience GmbH
 Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.
13
| Subsidiary | Pharmaceuticals: Major | 13 |
Ogeda SA
 Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.
12
| Subsidiary | Pharmaceuticals: Major | 12 |
GlaxoSmithKline Biologicals NV
 GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium.
10
| Subsidiary | Biotechnology | 10 |
Nouscom Srl
10
| Subsidiary | Miscellaneous Commercial Services | 10 |
Nouscom AG
 Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland.
10
| Holding Company | Pharmaceuticals: Major | 10 |
LEUKOCARE AG
 LEUKOCARE AG Medical/Nursing ServicesHealth Services LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany.
9
| Holding Company | Medical/Nursing Services | 9 |
PDC Line Pharma SASU
 PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.
8
| Holding Company | Pharmaceuticals: Major | 8 |
DNAlytics SA
 DNAlytics SA Data Processing ServicesTechnology Services DNAlytics SA engages in the development of data-driven precision medicine solutions. The firm provides consultancy services; and academic medical, biological, and clinical research laboratories for the pharmaceutical, biotechnology and In-Vitro Diagnostic companies. It also offers software programs unde rthe REED, LiblineaR, jForest, and BLISS brands. The company was founded by Pierre Dupont and Thibault Helleputte in 2012 and is headquartered in Louvain-la-Neuve, Belgium.
5
| Holding Company | Data Processing Services | 5 |
| Public Company | Biotechnology | 3 | |
| Subsidiary | Medical Specialties | 3 | |
20Med Therapeutics BV
 20Med Therapeutics BV BiotechnologyHealth Technology 20Med Therapeutics BV operates as a biomedical company. It focuses on the development of biodegradable materials for biomedical applications and multifunctional nanosystems for controlled drug and gene delivery. The company was founded by Johan F. J. Engbersen in 2011 and is headquartered in Enschede, the Netherlands.
2
| Holding Company | Biotechnology | 2 |
Henogen SA
 Henogen SA Pharmaceuticals: MajorHealth Technology Henogen SA develops and manufactures biopharmaceuticals. The company was founded on November 19, 1999 and is headquartered in Charleroi, Belgium.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Thémis SA
1
| Private Company | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Jean-Paul Prieels tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Private Equity Investor | |
PDC Line Pharma SA
 PDC Line Pharma SA Pharmaceuticals: MajorHealth Technology Part of PDC Line Pharma SASU, PDC Line Pharma is a Belgian company that focuses on medical needs, particularly on skin cancer, which is the most lethal form of cancer worldwide. The company is based in Liege, Belgium, and has two drug candidates in its pipeline, one for melanoma and another for lung cancer. The company aims to address this issue by developing drug candidates that can bring positive results to patients. PDC Line Pharma was founded in 2016 by Laurent Levy and Joel Plumas, and its CEO is Eric Halioua. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Founder Founder | |
| BEKAERT NV | Metal Fabrication | Director/Board Member Comptroller/Controller/Auditor Corporate Officer/Principal Corporate Officer/Principal | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal | |
Bioxodes SA
 Bioxodes SA Pharmaceuticals: MajorHealth Technology Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Epics Therapeutics SA
 Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | Miscellaneous Commercial Services | Founder Founder Chairman | |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member | |
| TIGENIX NV | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Bridge2Health SA
 Bridge2Health SA BiotechnologyHealth Technology Bridge2Health SA provides biomedical translational research services. It offers services to the clinicians, basic researchers and pharmaceutical industries. The firm also provides blueprint for biobank query and retrieval between universities. The company was founded in September 2012 and is headquartered in Liege, Belgium. | Biotechnology | Director/Board Member Chief Executive Officer | |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
Okairos AG
 Okairos AG Pharmaceuticals: MajorHealth Technology Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| MEDIGENE AG | Biotechnology | Director/Board Member Chairman | |
Novadip Biosciences SA
 Novadip Biosciences SA BiotechnologyHealth Technology Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
| University of Leiden | College/University | Graduate Degree Graduate Degree | |
| SANOFI | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| ZETES INDUSTRIES | Information Technology Services | Director/Board Member Sales & Marketing | |
| Tranzyme Pharma, Inc. (Canada) | Corporate Officer/Principal Corporate Officer/Principal | ||
| KUROS BIOSCIENCES AG | Biotechnology | Director of Finance/CFO Director/Board Member | |
Horama SA
 Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member | |
| Portuguese Catholic University | College/University | Undergraduate Degree Corporate Officer/Principal | |
| PROXIMUS SA | Major Telecommunications | Director/Board Member Corporate Officer/Principal | |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Guberna vzw
 Guberna vzw Miscellaneous Commercial ServicesCommercial Services Guberna vzw is an organization that aims to promote good governance in all types of organizations. The private company is based in Brussels, Belgium. The Belgian company believes that good governance leads to better organizations, which in turn contribute to a better world. To achieve this mission, Guberna focuses on three strategic pillars\: knowledge development, lifelong learning, and networking. Good governance involves boards, control, accountability, supervision, and control, and is a means to realize the organizational strategy. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
| NANEXA AB | Medical Specialties | Chairman Director/Board Member | |
| CELYAD ONCOLOGY SA | Biotechnology | Corporate Officer/Principal Director/Board Member | |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
| SCYNEXIS, INC. | Pharmaceuticals: Major | Founder Director/Board Member | |
Vermeg International NV
 Vermeg International NV Packaged SoftwareTechnology Services BSB International SA provides software and information technology services. It offers IT services for electronic document management, distribution web portals and third-party applications integration. The company was founded by Jean Martin, Michel Isaac, and Marc van Steenwinkel in December 1995 and is headquartered in Louvain-La-Neuve, Belgium. | Packaged Software | Director/Board Member Chief Executive Officer | |
Ncardia SA
 Ncardia SA Miscellaneous Commercial ServicesCommercial Services Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Callataÿ & Wouters Ventures SA | Investment Managers | Founder Founder | |
Synergia Medical SA
 Synergia Medical SA Packaged SoftwareTechnology Services Synergia Medical SA operates as a optoelectronics for neurostimulation medical devices. The company was founded by Attila Borbath and Pascal Doguet on September 26, 2013 and is headquartered in Mont-Saint-Guibert, Belgium. | Packaged Software | Director/Board Member Director/Board Member | |
| GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| APREA THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
iSTAR Medical SA
 iSTAR Medical SA Medical SpecialtiesHealth Technology iSTAR Medical SA develops innovative ophthalmic implants. Its products include MINIject, STARflo and STAR Material. The company was founded by Michel Alvarez in 2011 and is headquartered in Wavre, Belgium. | Medical Specialties | Director/Board Member Director/Board Member | |
| The American University of Rome | College/University | Doctorate Degree Corporate Officer/Principal | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal |
Statistiche
Distribuzione geografica
| Belgio | 22 |
| Svizzera | 7 |
| Francia | 7 |
| Stati Uniti | 6 |
| Paesi Bassi | 4 |
Settori
| Health Technology | 33 |
| Consumer Services | 7 |
| Commercial Services | 4 |
| Technology Services | 4 |
| Finance | 3 |
Posizioni
| Director/Board Member | 606 |
| Corporate Officer/Principal | 164 |
| Chairman | 122 |
| Chief Executive Officer | 86 |
| Independent Dir/Board Member | 67 |
Contatti più connessi
| Insiders | |
|---|---|
| Daniel Hugues Jules Gauthier | 49 |
| Gaëtan Hannecart | 46 |
| Göran Albert Ando | 44 |
| François Fontaine | 34 |
| Regina Hodits | 34 |
| Scott Rocklage | 32 |
| Alain Parthoens | 29 |
| Willem Frans Alfons van Twembeke | 29 |
| Mounia Chaoui-Roulleau | 27 |
| Gerhard Ries | 27 |
| Benoît Godts | 26 |
| Guido Magni | 23 |
| Harry Welten | 22 |
| Joachim Rothe | 22 |
| Eddy Hartung | 21 |
- Borsa valori
- Insiders
- Jean-Paul Prieels
- Connessioni Società
